Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally.
The last earnings update was 50 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Clovis Oncology. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Clovis Oncology's earnings available for a low price, and how does
this compare to other companies in the same industry?
Clovis Oncology's earnings are expected to grow significantly at over 20% yearly.
Clovis Oncology's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Clovis Oncology's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. on April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Officer of Pharmion GmbH. He founded Pharmion LLC in August 1999 and served as its Chief Executive Officer and President since August 1999. He has significant biotechnology and pharmaceutical executive management experience. From June 1992 to 1998, he served as the Chief Executive Officer and President of NeXagen, Inc., and its successor, NeXstar Pharmaceuticals, Inc. He served at E.M. Warburg, Pincus & Co., LLC since 1986, where served as a Vice President. Mr. Mahaffy is credited for developing corporate partnerships with Eli Lilly and Co., Systemix/Sandoz, Schering AG and Becton, Dickinson and Co. He served as the Chairman of Gritstone Oncology Inc. till May 2018. He has been the Chairman of Flexion Therapeutics, Inc. (formerly, Flexion Development Partners, Inc) since 2009. He served as Chairman of Orexigen Therapeutics, Inc. since April 2016 and its Director since February 2009 until July 27, 2018. He served as the Chairman of Psyadon Pharmaceuticals, Inc. He has been a Director of Flexion Therapeutics, Inc., since 2009; Pharmion LLC, since August 1999 and Clovis Oncology, Inc. since April 20, 2009. He serves as a Trustee of Lewis and Clark College. He served as a Director of NeXstar Pharmaceuticals, Inc. since 1991. He served as a Director of Psyadon Pharmaceuticals, Inc. Mr. Mahaffy received a B.A. in International Affairs from Lewis and Clark College and an M.A. in International Affairs from Columbia University.
Patrick's compensation has increased whilst company is loss making.
Patrick's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Clovis Oncology management team is about average.
Executive VP of Finance
Executive VP of Clinical
Chief Compliance Officer
Vice President of Investor Relations & Corporate Communications
Executive Vice President of Human Resources
Vice President of Investor Relations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Clovis Oncology board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.